Corporate acquisition activity through 2027 remains closely tied to monetary policy and financing conditions. Lower Fed funds rates and Treasury yields have reduced borrowing costs, supporting deal flow after earlier rate hikes compressed valuations. Recent inflation readings and labor market data continue to shape expectations for further easing, directly affecting implied probabilities on timing and scale of transactions. Antitrust reviews and regulatory approvals represent key hurdles, especially in technology and healthcare, where comparable deals have faced extended timelines. Traders are watching upcoming FOMC communications, corporate earnings releases, and any shifts in M&A volume or announced pipelines for signals on whether activity accelerates before year-end 2026. Market-implied odds reflect capital-weighted sentiment on these fundamentals rather than certainties.